Duloxetine vs. Pregabalin for Nerve Pain in Personal Injury Cases

James Wong — Founder & Pharmacist, LienScripts | February 18, 2026 | 8 min read

A clinical comparison of duloxetine (Cymbalta) and pregabalin (Lyrica) for neuropathic pain in personal injury cases — how each drug works, when prescribers choose one over the other, and what these medications signal on a pharmacy lien.

Duloxetine vs. Pregabalin: Managing Nerve Pain After a Personal Injury

Nerve pain — clinically described as neuropathic pain — is one of the most challenging sequelae of personal injury. Whether caused by a herniated disc compressing a spinal nerve root, peripheral nerve damage from a crush injury, or central sensitization following prolonged trauma, neuropathic pain often outlasts the acute injury and requires pharmacological treatment that goes beyond standard NSAIDs or opioids.

Two medications that frequently appear in pharmacy lien records for PI cases involving nerve pain are duloxetine (Cymbalta) and pregabalin (Lyrica). Both have FDA approval specifically for neuropathic pain indications, both are commonly prescribed by pain management physicians and neurologists treating injured patients, and both carry distinct pharmacological profiles that attorneys and case managers should understand.

What Is Neuropathic Pain in the Personal Injury Context?

Neuropathic pain arises from damage or dysfunction in the somatosensory nervous system — the network of nerves that processes sensation from the body to the brain. In PI cases, it commonly results from:

Radiculopathy — nerve root compression from disc herniation or spinal stenosis after a fall or MVA
Peripheral nerve injury — direct trauma to peripheral nerves in crush injuries, lacerations, or compartment syndrome
Traumatic brain injury (TBI) — central pain syndromes and post-TBI headache with neuropathic features
Complex Regional Pain Syndrome (CRPS) — a severe neuropathic condition sometimes triggered by limb injury
Post-surgical neuropathy — nerve damage following orthopedic or spinal surgery

Neuropathic pain is characteristically described as burning, shooting, electric, or stabbing — and is often accompanied by allodynia (pain from normally non-painful stimuli) and hyperalgesia (exaggerated pain response). Standard analgesics are often ineffective, requiring medications with specific mechanisms targeting the nervous system.

Duloxetine: Mechanism and Indications

Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI). While widely known as an antidepressant, duloxetine's analgesic effects are largely independent of its mood effects and derive from its enhancement of descending pain inhibitory pathways in the spinal cord. By increasing the availability of norepinephrine and serotonin in the dorsal horn of the spinal cord, duloxetine amplifies the brain's natural ability to dampen pain signals.

FDA-approved pain indications for duloxetine:

Diabetic peripheral neuropathic pain
Fibromyalgia
Chronic musculoskeletal pain (including chronic low back pain)

Though not FDA-approved specifically for post-traumatic radiculopathy, duloxetine is widely used off-label for these conditions and is supported by evidence in the clinical literature. In PI cases, it is commonly prescribed for:

Lumbar or cervical radiculopathy
Chronic pain following orthopedic injury
Overlapping anxiety or depression (common comorbidities in serious injury cases)
Fibromyalgia or central sensitization emerging from an acute traumatic injury

[!SOURCE] A systematic review published in JAMA found duloxetine effective for chronic musculoskeletal pain conditions, with a meaningful reduction in pain scores versus placebo. Citrome L, Weiss-Citrome A. A systematic review of duloxetine for osteoarthritic pain. Postgrad Med. 2012;124(1):83-93. https://pubmed.ncbi.nlm.nih.gov/22314117/

Pregabalin: Mechanism and Indications

Pregabalin is an alpha-2-delta calcium channel ligand. It works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters (glutamate, substance P, norepinephrine) from hyperactive neurons. This mechanism essentially "calms down" sensitized nerves that are firing excessively after injury.

FDA-approved pain indications for pregabalin:

Neuropathic pain associated with diabetic peripheral neuropathy
Postherpetic neuralgia
Fibromyalgia
Neuropathic pain associated with spinal cord injury

The spinal cord injury indication is particularly relevant to personal injury cases — pregabalin is one of very few FDA-approved treatments for that specific population. In PI cases, pregabalin is commonly prescribed for:

Radiculopathy with significant neuropathic features
Spinal cord injury (partial or complete)
Post-surgical neuropathic pain
CRPS
Chronic pain with anxiety (pregabalin has FDA approval for generalized anxiety disorder as well)

[!SOURCE] The FDA prescribing information for pregabalin (Lyrica) confirms the indication for neuropathic pain associated with spinal cord injury. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021446s035,022488s013lbl.pdf

Side Effect Profiles Compared

Both drugs are generally well tolerated but carry distinct side-effect burdens relevant to injured patients:

Duloxetine side effects:

Nausea (particularly on initiation — often transient)
Dry mouth
Fatigue
Increased sweating
Elevated blood pressure (requires monitoring)
Sexual dysfunction
Rare but serious: serotonin syndrome (especially with other serotonergic agents), hepatotoxicity in patients with liver disease

Pregabalin side effects:

Dizziness and somnolence (very common — can impair driving and daily function)
Peripheral edema (swelling of extremities)
Weight gain with prolonged use
Cognitive blunting ("brain fog")
Potential for misuse/dependence (Schedule V controlled substance)
Blurred vision

[!KEY] Pregabalin is classified as a DEA Schedule V controlled substance due to its potential for misuse. While less restrictive than Schedule II drugs, this classification affects pharmacy dispensing requirements and appears on controlled substance prescription monitoring program (PDMP) reports — a consideration in both clinical management and legal review of pharmacy lien records.

Duloxetine is not a controlled substance, which simplifies dispensing logistics. For patients who are also on opioids or other controlled substances, a non-controlled analgesic like duloxetine may be preferred to reduce overall controlled substance burden.

How Prescribers Choose Between Them

The choice between duloxetine and pregabalin in PI cases is typically driven by:

Type of neuropathic pain: Pregabalin is often preferred for more severe or acute neuropathic pain (e.g., post-surgical, spinal cord injury) due to its faster onset of action. Duloxetine may be favored for chronic, mixed musculoskeletal-neuropathic pain.
Comorbid conditions: If the patient has comorbid depression or anxiety — extremely common in serious injury cases — duloxetine addresses both pain and mood. If the patient has comorbid anxiety without depression, pregabalin's anxiolytic properties may be preferred.
Side effect tolerance: Patients who cannot tolerate dizziness or sedation may do better on duloxetine. Patients who cannot tolerate nausea may do better on pregabalin.
Prior treatment history: Many prescribers try one agent first, then add or switch to the other if response is inadequate. Combination therapy (both duloxetine and pregabalin) is sometimes used for refractory neuropathic pain, and both will appear on the same pharmacy lien.
Drug interactions: Duloxetine has a broader interaction profile (CYP1A2, CYP2D6) that may limit use in patients on certain medications. Pregabalin has minimal drug interactions, making it easier to add to complex medication regimens.

What These Medications Signal in a Pharmacy Lien

When duloxetine or pregabalin appears in a pharmacy lien, it is a clinical signal that the treating physician has identified a neuropathic component to the patient's pain — a finding that has important implications for case value:

Neuropathic pain diagnoses (radiculopathy, CRPS, peripheral neuropathy) typically support higher damages than soft-tissue-only injuries
Neuropathic conditions often require longer treatment duration, increasing documented medical necessity
The presence of these medications corroborates nerve injury findings on EMG/NCS studies or MRI, strengthening the overall case narrative

Attorneys should look for alignment between:

The prescribing physician's notes (pain assessment, diagnosis codes)
Imaging or electrodiagnostic studies (MRI, EMG/NCS)
The specific indication supported by FDA labeling or off-label evidence

A well-documented neuropathic pain medication regimen — with appropriate specialist oversight, monitoring visits, and dose titration — is entirely defensible in the context of a serious personal injury case.

[!KEY] Finding both duloxetine and pregabalin on the same lien is not unusual and should not automatically raise a red flag. Combination neuropathic therapy is guideline-supported for inadequate response to monotherapy, provided the prescriber has documented the rationale.

Summary

Duloxetine is an SNRI that enhances descending pain inhibition — preferred for chronic mixed pain, comorbid mood disorders, and patients who cannot tolerate sedation. Not a controlled substance.
Pregabalin is an alpha-2-delta ligand that calms hyperactive pain-signaling neurons — preferred for acute/severe neuropathic pain, spinal cord injury, and patients with comorbid anxiety. Schedule V controlled substance.
Both are clinically appropriate and commonly prescribed after serious personal injury, particularly when nerve injury or radiculopathy is present.
Their presence on a pharmacy lien supports a neuropathic pain diagnosis that typically correlates with higher injury severity and stronger case value.

Related Resources

Frequently Asked Questions

Is duloxetine an antidepressant or a pain medication in personal injury cases?

Duloxetine is both. It is FDA-approved for neuropathic pain conditions and chronic musculoskeletal pain, independent of any antidepressant effect. When a PI prescriber orders duloxetine for a patient with radiculopathy or chronic post-traumatic pain, it is prescribed for its analgesic mechanism — not for psychiatric treatment, even if the patient is also experiencing injury-related depression.

Why is pregabalin a controlled substance but duloxetine is not?

Pregabalin is DEA Schedule V because it carries a recognized potential for euphoria and misuse at high doses — particularly in patients with substance use history. Duloxetine acts on serotonin and norepinephrine systems and does not produce euphoric effects, so it is not scheduled. This distinction affects prescription monitoring requirements but does not change the clinical legitimacy of either drug in a PI lien.

Can a patient be on both duloxetine and pregabalin at the same time?

Yes. Combination therapy is sometimes used when monotherapy with either drug provides inadequate relief. The two drugs have complementary mechanisms and minimal pharmacokinetic interaction with each other. The prescriber should document the rationale (inadequate response to the first agent, specific features of the pain syndrome) to support medical necessity for both on the pharmacy lien.

How do I know if a nerve pain medication is medically justified in my client's case?

Look for corroborating evidence: MRI findings showing nerve compression or damage, an EMG/NCS showing nerve conduction abnormalities, or a specialist (neurologist, pain management physician) documenting neuropathic features in their clinical notes. When the medication choice aligns with the documented diagnosis, the lien is on solid ground.

How long do patients typically stay on duloxetine or pregabalin after an injury?

Duration varies significantly by injury severity and treatment response. Acute radiculopathy from a herniated disc may resolve with 3–6 months of treatment. Permanent nerve damage from spinal cord injury or CRPS may require indefinite treatment. Longer courses are supportable when the medical record documents ongoing symptoms, functional limitations, and periodic prescriber reassessment.